Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Niagen Bioscience's EBITDA for the
three
months ended in Mar. 2026 was €1.8 Mil. Niagen Bioscience's Revenue for the
three
months ended in Mar. 2026 was €27.2 Mil. Therefore, Niagen Bioscience's EBITDA margin for the quarter that ended in Mar. 2026 was 6.48%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Niagen Bioscience EBITDA Margin % Related Terms
Niagen Bioscience EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Niagen Bioscience's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:OCD1 vs LCTX, IFRX, VRXA: EBITDA Margin % Comparison
For the Biotechnology subindustry, Niagen Bioscience's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Niagen Bioscience EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Niagen Bioscience's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Niagen Bioscience's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Niagen Bioscience (FRA:OCD1) has a EBITDA Margin % of 6.48% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Niagen Bioscience and its competitors. According to the industry distribution chart, Niagen Bioscience ranks #241 out of 940 companies in the Biotechnology industry, placing it in the top 25.6%.
Is Niagen Bioscience's EBITDA Margin % too high?
Niagen Bioscience's current EBITDA Margin % is 6.48%. Based on the distribution chart, Niagen Bioscience ranks #241 out of 940 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Niagen Bioscience has a GF Score™ of 67/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Niagen Bioscience's EBITDA Margin % compare to LCTX and IFRX?
According to the Biotechnology industry distribution chart, Niagen Bioscience ranks #241 out of 940 companies for EBITDA Margin %. This puts Niagen Bioscience in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Niagen Bioscience and its competitors. Niagen Bioscience's current EBITDA Margin % is 6.48%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Niagen Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Niagen Bioscience (FRA:OCD1) is currently considered Possible Value Trap. The stock's GF Value™ is €3.98, compared to a current price of €2.58 — trading 35.2% below its estimated fair value. The current EBITDA Margin % is 6.48%. Niagen Bioscience's overall GF Score™ is 67/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Niagen Bioscience (FRA:OCD1), the current EBITDA Margin % is 6.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Niagen Bioscience (FRA:OCD1) Overvalued in 2026?
Based on GuruFocus' analysis, Niagen Bioscience stock appears to be undervalued.
The current stock price of €2.58 is trading 35.2% below its estimated GF Value™ of €3.98.
GuruFocus considers Niagen Bioscience to be Possible Value Trap.
Key valuation signals for FRA:OCD1:
EBITDA Margin %: 6.48%
GF Value™: €3.98 vs. price of €2.58 (35.2% below fair value)
No single metric tells the full story. See the FRA:OCD1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
67GF Score
Get the complete analysis for FRA:OCD1
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:OCD1 has been successfully added to your 
